The SARS-CoV-2 coronavirus is a new coronavirus that has sparked a worldwide pandemic with high rates of morbidity and mortality. The virus's rapid spread has highlighted the urgent need for potent treatments to stop COVID-19. A thorough analysis of these in silico methodologies is necessary to comprehend drug development for COVID-19 since computational methods have been essential in finding possible therapeutic targets and inhibitors for SARS-CoV-2. This article offers a thorough summary of the in-silico methods used to find prospective SARS-CoV-2 therapeutic targets and inhibitors. First, we discuss the mechanisms by which SARS-CoV-2 penetrates human cells as well as potential targets and receptors for the virus. The FDA-approved inhibitors and additional possible inhibitors that have been found through in silico investigations are then briefly discussed. Hydroxychloroquine, Remdesivir, Ribavirin, Tocilizumab